BACKGROUND: To identify additional at-risk groups for lung cancer screening, which targets persons with a long history of smoking and thereby misses younger or nonsmoking cases, the authors evaluated germline pathogenic variants (PVs) in patients with lung adenocarcinoma for an association with an accelerated onset. METHODS: The authors assembled a retrospective cohort (1999-2018) of oncogenetic clinic patients with lung adenocarcinoma. Eligibility required a family history of cancer, data on smoking, and a germline biospecimen to screen via a multigene panel. Germline PVs (TP53/EGFR, BRCA2, other Fanconi anemia [FA] pathway genes, and non-FA DNA repair genes) were interrogated for associations with the age at diagnosis via an accelerated failure time model. RESULTS: Subjects (n = 187; age, 28-89 years; female, 72.7%; Hispanic, 11.8%) included smokers (minimum of 5 pack-years; n = 65) and nonsmokers (lighter ever smokers [n = 18] and never smokers [n = 104]). Overall, 26.7% of the subjects carried 1 to 2 germline PVs: TP53 (n = 5), EGFR (n = 2), BRCA2 (n = 6), another FA gene (n = 11), or another DNA repair gene (n = 28). After adjustment for smoking, sex, and ethnicity, the diagnosis of lung adenocarcinoma was accelerated 12.2 years (95% confidence interval [CI], 2.5-20.6 years) by BRCA2 PVs, 9.0 years (95% CI, 0.5-16.5 years) by TP53/EGFR PVs, and 6.1 years (95% CI, -1.0 to 12.6 years) by PVs in other FA genes. PVs in other DNA repair genes showed no association. Germline associations did not vary by smoking. CONCLUSIONS: Among lung adenocarcinoma cases, germline PVs (TP53, EGFR, BRCA2, and possibly other FA genes) may be associated with an earlier onset. With further study, the criteria for lung cancer screening may need to include carriers of high-risk PVs, and findings could influence precision therapy and reduce lung cancer mortality by earlier stage diagnosis.
BACKGROUND: To identify additional at-risk groups for lung cancer screening, which targets persons with a long history of smoking and thereby misses younger or nonsmoking cases, the authors evaluated germline pathogenic variants (PVs) in patients with lung adenocarcinoma for an association with an accelerated onset. METHODS: The authors assembled a retrospective cohort (1999-2018) of oncogenetic clinic patients with lung adenocarcinoma. Eligibility required a family history of cancer, data on smoking, and a germline biospecimen to screen via a multigene panel. Germline PVs (TP53/EGFR, BRCA2, other Fanconi anemia [FA] pathway genes, and non-FA DNA repair genes) were interrogated for associations with the age at diagnosis via an accelerated failure time model. RESULTS: Subjects (n = 187; age, 28-89 years; female, 72.7%; Hispanic, 11.8%) included smokers (minimum of 5 pack-years; n = 65) and nonsmokers (lighter ever smokers [n = 18] and never smokers [n = 104]). Overall, 26.7% of the subjects carried 1 to 2 germline PVs: TP53 (n = 5), EGFR (n = 2), BRCA2 (n = 6), another FA gene (n = 11), or another DNA repair gene (n = 28). After adjustment for smoking, sex, and ethnicity, the diagnosis of lung adenocarcinoma was accelerated 12.2 years (95% confidence interval [CI], 2.5-20.6 years) by BRCA2 PVs, 9.0 years (95% CI, 0.5-16.5 years) by TP53/EGFR PVs, and 6.1 years (95% CI, -1.0 to 12.6 years) by PVs in other FA genes. PVs in other DNA repair genes showed no association. Germline associations did not vary by smoking. CONCLUSIONS: Among lung adenocarcinoma cases, germline PVs (TP53, EGFR, BRCA2, and possibly other FA genes) may be associated with an earlier onset. With further study, the criteria for lung cancer screening may need to include carriers of high-risk PVs, and findings could influence precision therapy and reduce lung cancer mortality by earlier stage diagnosis.
Authors: Daphne W Bell; Ira Gore; Ross A Okimoto; Nadia Godin-Heymann; Raffaella Sordella; Roseann Mulloy; Sreenath V Sharma; Brian W Brannigan; Gayatry Mohapatra; Jeff Settleman; Daniel A Haber Journal: Nat Genet Date: 2005-10-30 Impact factor: 38.330
Authors: S Mazoyer; A M Dunning; O Serova; J Dearden; N Puget; C S Healey; S A Gayther; J Mangion; M R Stratton; H T Lynch; D E Goldgar; B A Ponder; G M Lenoir Journal: Nat Genet Date: 1996-11 Impact factor: 38.330
Authors: Adi Gazdar; Linda Robinson; Dwight Oliver; Chao Xing; William D Travis; Junichi Soh; Shinichi Toyooka; Lori Watumull; Yang Xie; Kemp Kernstine; Joan H Schiller Journal: J Thorac Oncol Date: 2014-04 Impact factor: 15.609
Authors: James H Suh; Adrienne Johnson; Lee Albacker; Kai Wang; Juliann Chmielecki; Garrett Frampton; Laurie Gay; Julia A Elvin; Jo-Anne Vergilio; Siraj Ali; Vincent A Miller; Philip J Stephens; Jeffrey S Ross Journal: Oncologist Date: 2016-05-05
Authors: Yanhong Liu; Christine M Lusk; Michael H Cho; Edwin K Silverman; Dandi Qiao; Ruyang Zhang; Michael E Scheurer; Farrah Kheradmand; David A Wheeler; Spiridon Tsavachidis; Georgina Armstrong; Dakai Zhu; Ignacio I Wistuba; Chi-Wan B Chow; Carmen Behrens; Claudio W Pikielny; Christine Neslund-Dudas; Susan M Pinney; Marshall Anderson; Elena Kupert; Joan Bailey-Wilson; Colette Gaba; Diptasri Mandal; Ming You; Mariza de Andrade; Ping Yang; John K Field; Triantafillos Liloglou; Michael Davies; Jolanta Lissowska; Beata Swiatkowska; David Zaridze; Anush Mukeriya; Vladimir Janout; Ivana Holcatova; Dana Mates; Sasa Milosavljevic; Ghislaine Scelo; Paul Brennan; James McKay; Geoffrey Liu; Rayjean J Hung; David C Christiani; Ann G Schwartz; Christopher I Amos; Margaret R Spitz Journal: J Thorac Oncol Date: 2018-07-04 Impact factor: 15.609
Authors: Jeffrey N Weitzel; Kathleen R Blazer; Deborah J MacDonald; Julie O Culver; Kenneth Offit Journal: CA Cancer J Clin Date: 2011-08-19 Impact factor: 508.702
Authors: Barbara G Campling; Wei-Ting Hwang; Jiameng Zhang; Stephanie Thompson; Leslie A Litzky; Anil Vachani; Ilene M Rosen; Kenneth M Algazy Journal: Cancer Date: 2005-08-15 Impact factor: 6.860
Authors: D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky Journal: Science Date: 1990-11-30 Impact factor: 47.728
Authors: Shih-Jen Hwang; Li Shu-Chung Cheng; Guillermina Lozano; Christopher I Amos; Xiangjun Gu; Louise C Strong Journal: Hum Genet Date: 2003-06-11 Impact factor: 4.132
Authors: Jiyoun Yeo; Erin L Crawford; Xiaolu Zhang; Sadik Khuder; Tian Chen; Albert Levin; Thomas M Blomquist; James C Willey Journal: BMC Cancer Date: 2017-05-02 Impact factor: 4.430